Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 3/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5196713 | 0.82 | XDH (0.54) | XDHHDAC1HDAC2NPC1GLA | |
| SCHEMBL7052324 | 0.81 | HDAC1 (0.61) | XDHHDAC1HDAC2AURKANPC1 | |
| SCHEMBL5192969 | 0.81 | HDAC1 (0.61) | XDHHDAC1HDAC2AURKANPC1 | |
| SCHEMBL5694220 | 0.78 | XDH (0.65) | XDHSMN1; SMN2TMIGD3HTR2CHTR2B | |
| SCHEMBL5352883 | 0.76 | XDH (0.67) | XDHNPC1SMN1; SMN2 | |
| SCHEMBL6899619 | 0.76 | POLA1 (0.53) | XDHHDAC1HDAC2 | |
| SCHEMBL5694094 | 0.73 | XDH (0.51) | XDHNPC1SMN1; SMN2TMIGD3HTR2C | |
| SCHEMBL16146631 | 0.72 | XDH (0.65) | XDHSMN1; SMN2TMIGD3HTR2CHTR2B | |
| SCHEMBL7110910 | 0.72 | XDH (0.69) | XDHSMN1; SMN2TMIGD3HTR2CHTR2B | |
| SCHEMBL6996417 | 0.71 | XDH (0.62) | XDHNPC1GLAMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207419-A1 | SOLID FORM OF 2-CHLORO-2'-DEOXY-ADENOSINE COMPLEX WITH HPßCD | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2024-06-27 | — | — | US | disclosed |
| EP-1554298-A4 | PROCESS FOR THE PREPARATION OF 9-BETA-ANOMERIC NUCLEOSIDE ANALOGS | ASH STEVENS INC (US) | 2007-09-26 | — | — | EP | disclosed |
| EP-1554298-A1 | PROCESS FOR THE PREPARATION OF 9-BETA-ANOMERIC NUCLEOSIDE ANALOGS | ASH STEVENS, INC. (US) | 2005-07-20 | — | — | EP | disclosed |
| US-6884880-B2 | Process for the preparation of 9-β-anomeric nucleoside analogs | ASH STEVENS, INC. (US) | 2005-04-26 | — | — | US | disclosed |
| WO-2004018490-A1 | PROCESS FOR THE PREPARATION OF 9-BETA-ANOMERIC NUCLEOSIDE ANALOGS | ASH STEVENS, INC. (US) | 2004-03-04 | — | — | WO | disclosed |
| US-20040039190-A1 | Process for the preparation of 9-beta-anomeric nucleoside analogs | ASH STEVENS, INC. | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207419-A1 | SOLID FORM OF 2-CHLORO-2'-DEOXY-ADENOSINE COMPLEX WITH HPßCD | DCTD, AMPD2, ADA | XDH 1267/4885HDAC1 1292/4885HDAC2 801/4885 |
| US-20040039190-A1 | Process for the preparation of 9-beta-anomeric nucleoside analogs | DPYD, SLC29A2, GALE | XDH 339/4885HDAC1 4493/4885HDAC2 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.